Sicart Associates LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 7,389 shares of the healthcare product maker’s stock, valued at approximately $422,000.

A number of other institutional investors have also recently made changes to their positions in ABT. Eagle Ridge Investment Management raised its position in shares of Abbott Laboratories by 5.2% in the 2nd quarter. Eagle Ridge Investment Management now owns 197,488 shares of the healthcare product maker’s stock worth $8,849,000 after purchasing an additional 9,760 shares during the last quarter. Callahan Advisors LLC raised its position in shares of Abbott Laboratories by 13.8% in the 2nd quarter. Callahan Advisors LLC now owns 93,985 shares of the healthcare product maker’s stock worth $4,569,000 after purchasing an additional 11,412 shares during the last quarter. Retirement Systems of Alabama raised its position in shares of Abbott Laboratories by 0.5% in the 2nd quarter. Retirement Systems of Alabama now owns 1,309,756 shares of the healthcare product maker’s stock worth $63,667,000 after purchasing an additional 6,070 shares during the last quarter. Chicago Partners Investment Group LLC raised its position in shares of Abbott Laboratories by 124.1% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 15,237 shares of the healthcare product maker’s stock worth $688,000 after purchasing an additional 8,437 shares during the last quarter. Finally, Palladium Partners LLC raised its position in shares of Abbott Laboratories by 0.6% in the 2nd quarter. Palladium Partners LLC now owns 54,242 shares of the healthcare product maker’s stock worth $2,637,000 after purchasing an additional 304 shares during the last quarter. 70.61% of the stock is owned by institutional investors and hedge funds.

Several equities analysts have recently issued reports on ABT shares. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price target for the company in a research report on Tuesday, October 31st. Royal Bank of Canada reaffirmed a “buy” rating and issued a $65.00 price target on shares of Abbott Laboratories in a research report on Tuesday, January 9th. BMO Capital Markets raised Abbott Laboratories from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $58.00 to $65.00 in a research report on Tuesday, December 12th. Morgan Stanley raised Abbott Laboratories from an “equal weight” rating to an “overweight” rating and set a $67.00 price target for the company in a research report on Tuesday, January 2nd. Finally, JPMorgan Chase & Co. raised Abbott Laboratories from a “neutral” rating to an “overweight” rating and set a $60.00 price target for the company in a research report on Tuesday, January 2nd. Eight investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $65.47.

In other Abbott Laboratories news, insider Alejandro D. Wellisch sold 2,153 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the completion of the sale, the insider now directly owns 10,256 shares in the company, valued at approximately $572,900.16. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Miles D. White sold 276,886 shares of the business’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $54.41, for a total value of $15,065,367.26. Following the sale, the chairman now owns 3,677,913 shares of the company’s stock, valued at $200,115,246.33. The disclosure for this sale can be found here. In the last three months, insiders sold 374,458 shares of company stock valued at $20,752,706. 0.76% of the stock is owned by insiders.

Abbott Laboratories (ABT) opened at $57.64 on Wednesday. Abbott Laboratories has a 52-week low of $42.31 and a 52-week high of $64.60. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. The firm has a market capitalization of $100,330.00, a PE ratio of 288.20, a price-to-earnings-growth ratio of 1.72 and a beta of 1.55.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The business had revenue of $7.59 billion during the quarter, compared to analyst estimates of $7.38 billion. During the same quarter in the previous year, the firm earned $0.65 EPS. Abbott Laboratories’s revenue was up 42.3% on a year-over-year basis. equities analysts forecast that Abbott Laboratories will post 2.86 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be given a $0.28 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $1.12 dividend on an annualized basis and a yield of 1.94%. Abbott Laboratories’s payout ratio is 560.00%.

ILLEGAL ACTIVITY NOTICE: “7,389 Shares in Abbott Laboratories (ABT) Acquired by Sicart Associates LLC” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/7389-shares-in-abbott-laboratories-abt-acquired-by-sicart-associates-llc/1866106.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.